La dermatite atopique (DA) est une dermatose inflammatoire dont la prévalence élevée est en constante augmentation dans les pays industrialisés. La physiopathologie de la DA est complexe et associe des facteurs immunologiques, environnementaux et génétiques. L'ensemble de ces facteurs touchent principalement l'épiderme et sont responsables d'une altération de la fonction barrière, ce qui facilite la pénétration transcutanée des molécules en contact avec la peau et la sensibilisation des individus. Ce travail de thèse vise à mieux caractériser le rôle de l'épiderme dans la physiopathologie de la DA. Il repose sur l'utilisation d'un modèle in vitro d'épiderme reconstruit humain généré à partir de cellules progénitrices de follicules pileux prélevés chez des patients atteints de DA, ainsi que chez des individus sains. Ce travail a tout d'abord montré que les épidermes DA générés à partir de patients non porteurs de mutations pour le gène de la filaggrine (FLG+/+) se comportaient comme des épidermes normaux, (i) tant à l'homéostasie, (ii) que suite à une stimulation par de l'interleukine-1beta (IL-1 β) ou par un allergène majeur de la DA, tel qu'un extrait d'acarien (Dermatophagoïdes farinae). Cependant, de façon très intéressante, les épidermes- DA se sont avérés davantage sensibles à l'apoptose induite par une exposition aux ultraviolets (UV), que les épidermes normaux. A cet égard, nous avons observé une modulation différente de certains gènes impliqués dans l'induction/régulation de l'apoptose par les épidermes provenant de patients DA après exposition aux UV. En outre, ce travail a démontré que des épidermes normaux sont profondément affectés par l'IL-1 β qui induit un phénotype atopique caractéristique associant (i) la production de quantité notable de TSLP (thymic stromal lymphopoietin) et (ii) une altération de la fonction barrière. L'impact de l'IL-1 β sur la biologie de l'épiderme et la sensibilité accrue exprimée par les épidermes-DA à l'apoptose induite par les UV sont donc de nouveaux éléments qui confirment l'importance de l'épiderme dans la physiopathologie de la DA ce qui permettra certainement de nouvelles stratégies thérapeutiques / Atopic dermatitis (AD) is an inflammatory skin disease with a high prevalence constantly increased in developed countries. The AD physiopathology is complex and associated with immunological, environmental and genetic factors. These factors impact mainly the epidermis and are responsible of the impaired barrier function which increases antigen penetration and people sensitization. The aim of this work is to improve the understanding of the epidermis role in AD physiopathology. For this, we used an in vitro reconstructed human epidermis model generated from outer root sheath cells taken off AD patients or normal individuals.First of all, this work has shown that epidermis generated from AD patients (AD- epidermis) with no mutation on filaggrine gene (FLG+/+) behave like those from normal individuals (Normal- epidermis), (i) at the steady state, and (ii) after stimulation with interleukin-1beta (IL-1 β) or a major allergen found in AD, Dermatophagoïdes farinae. However, interestingly, AD-epidermis are more sensitized to ultra-violets radiation-induced (UVR) apoptosis than Normal-epidermis. In this regard, we observed a higher expression of genes involved in the induction / regulation of apoptosis by the epidermis from AD patients after UV exposure. Moreover, this work has demonstrated that normal epidermis are profoundly affected by IL-1 β which induces an AD like phenotype associating (i) production of large amount of TLSP (thymic stromal lymphopoietin) and (ii) alterated barrier function. The impact of IL-1 β on epidermis biology and the increased sensitivity that seems to express AD-epidermis to UVR-induced apoptosis are new evidences that confirm the importance of the epidermis in pathophysiology of AD which certainly will lead to new therapeutic strategies

Orientador: Ronei Luciano Mamoni / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-27T05:56:25Z (GMT). No. of bitstreams: 1 Castro_LiviaFurquimde_M.pdf: 5966667 bytes, checksum: bd25c56ae25a8825069884bedd9ca8ce (MD5) Previous issue date: 2015 / Resumo: Diversos estudos demonstram que a resposta inflamatória é de extrema importância para o controle da Paracoccidioidomicose (PCM). Essa resposta inflamatória é iniciada pelo reconhecimento das células fúngicas por receptores expressos por células do sistema imunológico inato. Dentre esses receptores, o NLRP3 foi associado com o reconhecimento de fungos patogênicos em modelos experimentais, atuando em conjunto com o TLR2 e a dectina-1. O NLRP3 atua na formação de um complexo multiproteico denominado inflamassoma, o qual ativa a caspase-1, que é responsável pela produção das formas ativas de duas importantes citocinas inflamatórias: a IL-1? e a IL-18. Esse estudo teve por objetivo investigar o envolvimento do NLRP3 na ativação da resposta inflamatória de macrófagos e células dendríticas humanas (DCs) derivadas de monócitos em resposta ao Paracoccidioides brasiliensis (Pb), além de avaliar a participação do NLRP3 na indução da resposta imunológica adaptativa. Nossos resultados demonstraram que células de lesões de pacientes com PCM (mucosa oral ou linfonodos) apresentam produção de IL-1beta, IL-18 e IL-37 e que macrófagos dessas lesões são positivos para Caspase-1 e NLRP3. Também fomos capazes de demonstrar que o reconhecimento de células leveduriformes por DCs e macrófagos humanos leva à ativação do inflamassoma NLRP3 e consequente produção de IL-1 e IL-18. Esse reconhecimento envolve a participação de receptores de superfície (TLR2 e Dectina-1), sendo que a produção dessas citocinas é dependente da sinalização via dectina-1 e fosforilação da proteína Syk. Além disso, observamos que a ativação do inflamassoma NLRP3, após o reconhecimento do fungo, envolve como principais mecanismos a produção de ROS e o efluxo de K+. Nossos dados também demonstraram que o inflamassoma NLRP3 é essencial para a diferenciação de células Th17 e Th1 e que sua inibição leva à um aumento de células Th2 e Treg. Em conjunto nossos dados indicam que a ativação do NLRP3 desempenha um papel importante, tanto na indução de uma resposta inflamatória inicial, quanto no desenvolvimento de uma resposta adquirida que pode ser associada à resistência à infecção pelo P. brasiliensis / Abstract: Several studies have shown that the inflammatory response is crucial for the control of paracoccidioidomycosis (PCM). This inflammatory response is initiated by the recognition of fungal yeast cells by receptors expressed by cells of the innate immune system. Among these receptors, NLRP3 was associated with the recognition of pathogenic fungi in experimental models, working in conjunction with TLR2 and dectin-1. The NLRP3 acts forming a multiproteic complex called inflammasome, which activates caspase-1, and the production of the active forms of two important cytokines: IL-1? and IL-18. This study aimed to investigate the involvement of NLRP3 activation in the inflammatory response of macrophages and human dendritic cells (DCs) derived from monocytes, in response to Paracoccidioides brasiliensis (Pb), and to evaluate the participation of NLRP3 in the induction of the subsequent adaptive immune response. Our results demonstrated that cells of lesions from PCM patients (oral mucosa and lymph nodes) express IL-1beta, IL-18 and IL-37, and that macrophages in these lesions are positive for caspase-1 and NLRP3. We were also able to demonstrate that the recognition of Pb yeast cells by human macrophages and DCs leads to the NLRP3 inflammasome activation and production of IL-1 and IL-18. This recognition involves the participation of surface receptors (TLR2 and Dectin-1), and the production of these cytokines was dependent on signaling via dectin-1 and phosphorylation of Syk. In addition, we observed that the activation of the NLRP3 inflammasome, after recognition of the fungus, involves as main mechanisms the ROS production and the K+ efflux. Our data also demonstrate that the NLRP3 inflammasome are essential for the differentiation of Th1 and Th17 cells and its inhibition leads to an increased frequency of Th2 and Treg cells. Taken together our data indicated that activation of NLRP3 present an important role in both the induction of an initial inflammatory response, and in the development of an acquired immune response, which can be associated with the resistance to the P. brasiliensis infection / Mestrado / Ciencias Biomedicas / Mestra em Ciências Médicas

The development of autoinflammatory diseases is caused by the dysregulation of innate immune mechanisms. This leads to the development of spontaneous inflammation. Mice lacking adaptor protein PSTPIP2 develop chronic autoinflammatory osteomyelitis due to higher activity of neutrophil granulocytes and their increased production of IL-1β. .β. PSTPIP2 interacts with PEST phosphatases and kinase CSK. These proteins are impor- tant negative regulators of Src family kinases. In this diploma thesis, the role of Src family kinases and the role of their positive regulator phosphatase CD45 in the development of chronic autoinflammatory osteomyelitis was studied. For this purpose, a mouse model of chronic autoinflammatory osteomyelitis (CMO) lacking CD45 was used. These mice deve- lop the disease with delayed kinetics. Bone marrow cells isolated from these mice produce less IL-1β. upon silica activation and have lower phosphorylation of ERK MAP kinase. It isβ. probably caused by higher phosphorylation of the inhibitory tyrosine of Src family kinases resulting in their lower activity. The presence of different immune cell populations in the bone marrow, spleen and blood of these mice was also monitored in these mice. The re- sults of this work contribute to a better understanding of the role of Src family...

No description available.

PGC-1 beta é um co-ativador de transcrição gênica responsável pela regulação do metabolismo celular, principalmente na biogênese e função mitocondrial, disponibilidade de substrato e síntese de lipídios. Nos últimos anos, outras isoformas de PGC-1 têm sido descritos como participantes na gênese e manutenção de tumores. Portanto, nosso objetivo foi determinar se o PGC-1beta está relacionado ao aumento da proliferação celular de células de melanoma. Inicialmente, foi demonstrado que os níveis de RNAm e proteína de PGC-1beta são muito mais elevados em linhagens de células de melanoma (Tm1 e Tm5) do que na linhagem parental de melanócitos não tumorais (Melan-a) como detectado por PCR quantitativa e western blotting. A fim de descobrir uma relação causal entre a expressão de PGC-1? e crescimento celular da linhagem Tm5, células de tal linhagem foram transfectadas com um oligonucleotídeo antisense (ASO) contra PGC-1beta. As células tratados com ASO apresentaram níveis mais baixos de RNAm e proteína PGC-1beta, além de redução em sua atividade avaliada pela expressão de genes PGC-1beta dependentes. Além disso, as células transfectadas apresentaram uma taxa de proliferação inferior em comparação com células de controle Tm5. Este fenômeno também foi observado in vivo. Quando injetadas em camundongos, as células Tm5 desenvolvem-se em um tumor que atinge 1,34 ± 0,20 cm3 após nove dias. Tumores tratados com ASO após o mesmo tempo apresentaram volume tumoral de 0,75 ± 0,05 cm3. Este crescimento não estava relacionada à necrose tumoral, mas sim com a proliferação reduzida de células. Finalmente, verificamos se o mesmo fenômeno seria observado em humanos. A expressão PGC-1beta foi muito maior em amostras de melanoma do que em nevos, alterações não-malignas da pele com alto conteúdo de melanina. Por conseguinte, conclui-se que a expressão PGC-1? está aumentada no melanoma, tanto murino e humano, e que o bloqueio da sua atividade leva à diminuição da proliferação celular e crescimento tumoral / PGC-1beta is a co-activator of gene transcription primarily responsible for the regulation of cellular metabolism, mainly in mitochondrial biogenesis and function and also substrate and lipid synthesis. In recent years, other isoforms of PGC-1 have been described as participating in the genesis and maintenance of tumors. Therefore, our objective was to determine whether PGC-1beta is related to increased proliferation of melanoma cells. Initially, it was demonstrated that mRNA and protein levels of PGC-1beta are much higher in melanoma cell lines (Tm1 and TM5) than in the non-tumoral parental lineage melanocytes (melan-a) as detected by quantitative PCR and Western blotting. In order to find a causal relationship between the expression of PGC-1beta and cell growth, Tm5 lineage cells were transfected with an antisense oligonucleotide (ASO) against PGC-1beta. The cells treated with ASO had lower levels of PGC-1beta mRNA and protein, as well as reduction in its activity detected by quantitation of PGC-1beta dependent genes expression. Furthermore, transfected cells showed a lower rate of proliferation compared to Tm5control cells. This phenomenon was also observed in vivo. When injected into mice, Tm5 cells develop a tumor which reaches 1.34 ± 0.20 cm3 after nine days. Tumors treated with ASO, after the same time, presented tumor volume of 0.75 ± 0.05 cm 3. This growth was not related to tumor necrosis, but with reduced cell proliferation. Finally, we checked whether the same phenomenon would be observed in humans. The PGC-1beta expression was much higher in melanoma samples than in nevi, a non-malignant skin alteration filled with melanin. Therefore, we concluded that PGC-1beta expression in melanoma is increased, both in murine and human, and that blocking its activity leads to decreased cell proliferation and tumor growth

Mehrere Studien haben gezeigt, daß die Cyclooxygenase-2 (COX-2) eine bedeutende Rolle sowohl bei Entstehung als auch Progression maligner Tumoren spielt. COX-2-Inhibitoren werden bereits in klinischen Studien zur Krebstherapie getestet. COX-2 ist die induzierbare Isoform der Cyclooxygenase - dem Schlüsselenzym der Synthese von Prostaglandinen und anderen Eicosanoiden. Im Tier- und Zellkulturmodell konnten COX-Hemmer anti-Tumor-Effekte hervorrufen. Es ist jedoch unklar, ob diese Effekte durch Hemmung des COX-Enzyms oder durch COX-unabhängige Mechanismen vermittelt werden. Wir untersuchten daher die Auswirkung der COX-Inhibition zum einen durch den selektiven COX-2-Hemmer NS-398 sowie zum anderen durch COX-Isoform-spezifische RNA-Interferenz (RNAi) in zwei humanen Ovarialkarzinomzellinien (OVCAR-3 und SKOV-3). OVCAR-3 zeigte eine konstitutive COX-1-Expression und eine durch IL-1beta induzierbare COX-2-Expression. SKOV-3 war COX-1- und COX-2-negativ. IL-1beta führte bei OVCAR-3 zu einer vermehrten Produktion von Prostaglandin E2 (PGE2), die durch eine gegen die COX-2 gerichtete siRNA gehemmt werden konnte, wohingegen COX-1-siRNA keinen Effekt hatte. Das deutet darauf hin, daß die COX-2 die Hauptquelle von PGE2 in OVCAR-3 ist. 1mikroM NS-398 waren ausreichend, um die PGE2-Produktion und somit auch die COX-2 in OVCAR-3 zu inhibieren. Höhere Konzentrationen NS-398 (>10mikroM) hatten einen antiproliferativen Effekt. Auch in der COX-2-negativen Zellinie SKOV-3 trat diese Wachstumshemmung auf; sie war nicht durch exogene Zufuhr von PGE2 (10mikroM) reversibel. Durchflußzytometrische Zellzyklusanalyse ergab, daß der Wachstumshemmung in beiden Zellinien ein G0/G1-Zellzyklusarrest zugrunde liegt. Dagegen führten weder COX-1- noch COX-2-Ausschaltung durch RNAi zu ähnlichen Auswirkungen auf Proliferation bzw. Zellzyklus. Diese Ergebnisse zeigen, dass ein COX-2-unabhängiger Mechanismus für den durch NS-398 induzierten G0/G1-Arrest verantwortlich ist. / Several studies have provided evidence that the enzyme Cyclooxygenase-2 (COX-2) plays an important role in tumor development and progression. COX-2-inhibitors are already evaluated in clinical trials as cancer therapeutics. COX-2 is the inducible isoform of cyclooxygenase - the rate-limiting enzyme in the synthesis of prostaglandins and other eicosanoids. COX-inhibitors cause antitumor effects in animal models and in cell culture experiments. However, it is not clear, whether these effects are due to inhibition of the COX-enzyme or mediated via a COX-independent mechanism. We therefore investigated the effects of COX inhibition by the selective COX-2-inhibitor NS-398, as well as by COX-isoform specific RNA interference (RNAi) in the human ovarian carcinoma cell lines OVCAR-3 and SKOV-3. OVCAR-3 cells showed a constitutive expression of COX-1, and an inducible COX-2 expression. COX-2 was induced through stimulation with Interleukin-1beta, leading to production of high levels of Prostaglandin E2 (PGE2). SKOV-3 cells were negative for both COX isoforms. Selective COX-2-suppression by RNAi reduced PGE2 production in OVCAR-3, whereas COX-1-siRNA had no effect on PGE2 synthesis. Thus, COX-2 is the main source of PGE2 in OVCAR-3 cells. In these cells, 1microM NS-398 was sufficient to completely inhibit PGE2-synthesis - and thus the activity of the COX-2 enzyme. Increasing amounts of NS-398 (>10microM) had an antiproliferative effect. This growth inhibition was also observed in the COX-negative cell line SKOV-3, it could not be reverted by exogenous addition of PGE2 (10microM). Flowcytometric analysis of the cell cycle revealed that this growth inhibition was based on a G0/G1-cell-cycle-arrest. In contrast, suppression of COX-1 or COX-2 by RNAi had no effect on proliferation or cell cycle progression. These results suggest that a COX-independent mechanism is responsible for the G0/G1-arrest induced by NS-398.

PGC-1 beta é um co-ativador de transcrição gênica responsável pela regulação do metabolismo celular, principalmente na biogênese e função mitocondrial, disponibilidade de substrato e síntese de lipídios. Nos últimos anos, outras isoformas de PGC-1 têm sido descritos como participantes na gênese e manutenção de tumores. Portanto, nosso objetivo foi determinar se o PGC-1beta está relacionado ao aumento da proliferação celular de células de melanoma. Inicialmente, foi demonstrado que os níveis de RNAm e proteína de PGC-1beta são muito mais elevados em linhagens de células de melanoma (Tm1 e Tm5) do que na linhagem parental de melanócitos não tumorais (Melan-a) como detectado por PCR quantitativa e western blotting. A fim de descobrir uma relação causal entre a expressão de PGC-1? e crescimento celular da linhagem Tm5, células de tal linhagem foram transfectadas com um oligonucleotídeo antisense (ASO) contra PGC-1beta. As células tratados com ASO apresentaram níveis mais baixos de RNAm e proteína PGC-1beta, além de redução em sua atividade avaliada pela expressão de genes PGC-1beta dependentes. Além disso, as células transfectadas apresentaram uma taxa de proliferação inferior em comparação com células de controle Tm5. Este fenômeno também foi observado in vivo. Quando injetadas em camundongos, as células Tm5 desenvolvem-se em um tumor que atinge 1,34 ± 0,20 cm3 após nove dias. Tumores tratados com ASO após o mesmo tempo apresentaram volume tumoral de 0,75 ± 0,05 cm3. Este crescimento não estava relacionada à necrose tumoral, mas sim com a proliferação reduzida de células. Finalmente, verificamos se o mesmo fenômeno seria observado em humanos. A expressão PGC-1beta foi muito maior em amostras de melanoma do que em nevos, alterações não-malignas da pele com alto conteúdo de melanina. Por conseguinte, conclui-se que a expressão PGC-1? está aumentada no melanoma, tanto murino e humano, e que o bloqueio da sua atividade leva à diminuição da proliferação celular e crescimento tumoral / PGC-1beta is a co-activator of gene transcription primarily responsible for the regulation of cellular metabolism, mainly in mitochondrial biogenesis and function and also substrate and lipid synthesis. In recent years, other isoforms of PGC-1 have been described as participating in the genesis and maintenance of tumors. Therefore, our objective was to determine whether PGC-1beta is related to increased proliferation of melanoma cells. Initially, it was demonstrated that mRNA and protein levels of PGC-1beta are much higher in melanoma cell lines (Tm1 and TM5) than in the non-tumoral parental lineage melanocytes (melan-a) as detected by quantitative PCR and Western blotting. In order to find a causal relationship between the expression of PGC-1beta and cell growth, Tm5 lineage cells were transfected with an antisense oligonucleotide (ASO) against PGC-1beta. The cells treated with ASO had lower levels of PGC-1beta mRNA and protein, as well as reduction in its activity detected by quantitation of PGC-1beta dependent genes expression. Furthermore, transfected cells showed a lower rate of proliferation compared to Tm5control cells. This phenomenon was also observed in vivo. When injected into mice, Tm5 cells develop a tumor which reaches 1.34 ± 0.20 cm3 after nine days. Tumors treated with ASO, after the same time, presented tumor volume of 0.75 ± 0.05 cm 3. This growth was not related to tumor necrosis, but with reduced cell proliferation. Finally, we checked whether the same phenomenon would be observed in humans. The PGC-1beta expression was much higher in melanoma samples than in nevi, a non-malignant skin alteration filled with melanin. Therefore, we concluded that PGC-1beta expression in melanoma is increased, both in murine and human, and that blocking its activity leads to decreased cell proliferation and tumor growth

Angiogenesis, the formation of new vessels from a preexisting vasculature, is critical for supplying a healing myocardium with oxygen and nutrients to sustain metabolism post myocardial infarction (MI). Interleukin-1β (IL-1β), a proinflammatory cytokine increased in the heart post-MI, is considered essential for angiogenesis in tumor growth and metastasis, arthritis, endometriosis, and wound healing. Matrix metalloproteinases (MMPs) are implicated in angiogenesis because of their ability to selectively degrade components of the extracellular matrix. Vascular endothelial growth factors (VEGFs) play a vital role in angiogenesis because of their involvement in the recruitment and proliferation of endothelial cells. The current study explores IL-1β-stimulated regulation of angiogenic genes in cardiac microvascular endothelial cells (CMECs), the signaling mechanisms involved, and the implications in the processes of angiogenesis. DNA microarray analysis indicated IL-1β modulates the expression of numerous angiogenesis-related genes, notably upregulating MMP-2 and downregulating VEGF-D expression. RT-PCR and Western blot analyses confirmed the differential expression in response to IL-1β. In-gel zymographic analysis demonstrated IL-1β-stimulated increase in MMP-2 activity. IL-1β activated ERK1/2 and JNKs, not p38 kinase, and activated PKCα/β1 independent of MAPKs. IL-1β inactivated GSK3β via ERK1/2. Pharmacological inhibition of these signaling cascades indicated IL-1β-stimulated regulation of MMP-2 and VEGF-D occurs via ERK1/2, JNKs, and PKCα/β1-dependent mechanisms. In addition, inactivation of GSK3β inhibited basal VEGF-D expression. H2O2 significantly increased MMP-2 protein levels while IL-1β-induced VEGF-D downregulation was further potentiated by ROS scavenging compounds and inhibition of NF-κB. Phalloidin-FITC stain indicated a sharp reduction in fibrillar actin in the cytoskeleton of IL-1β-stimulated cells. Wounding assays revealed that IL-1β induced CMEC migration but prevented cell-to-cell contact and restoration of the monolayer. Flow cytometric analysis revealed a G0/G1 phase cell cycle arrest in IL-1β-stimulated cells, indicative of decreased proliferation. IL-1β inhibited three-dimensional in vitro tube formation by CMECs. Lastly, IL-1β inhibited microvessel sprouting from aortic rings, an assay examining the collective response of multiple cell types. Collectively, the data presented in this study provide evidence that IL-1β differentially regulates important angiogenesis-related genes in CMECs. This differential regulation may lead to interruptions in the processes of angiogenesis, ultimately creating a dysfunctional phenotype for myocardial vessel formation.

Selon une étude précédente, une limitation à l'efficacité anticancéreuse du 5-Fluorouracile (5-FU) repose sur la sécrétion d'IL-1β par des cellules myéloïdes immunosuppressives (MDSC). La libération d'IL-1β mature provient de l'activation de NLRP3 induite par le 5- FU et de l’augmentation de l’activité de la caspase-1 dans les MDSC, qui favorise la reprise de la croissance tumorale chez des souris traitées avec 5-FU. L'acide docosahexaénoïque (DHA) appartient à la famille des acides gras oméga-3 et possède des propriétés anticancéreuses et anti-inflammatoires qui pourraient améliorer la chimiothérapie à base de 5-FU. Dans ces travaux, nous démontrons que le DHA inhibe la sécrétion d'IL 1β induite par le 5 FU dans une lignée cellulaire de MDSC (MSC-2). Chez des souris porteuses de tumeurs traitées par 5 FU, nous avons montré qu'un régime alimentaire enrichi en DHA réduit la concentration d'IL 1β circulante et la récidive tumorale après une injection de 5 FU. Le traitement par 5 FU conduit à l'activation de JNK dans les MDSC et l'inhibiteur de JNK SP600125 diminue la sécrétion d’IL-1β. De plus, le DHA est capable de contrecarrer l'activation de JNK induite par 5-FU dans les MDSC, entraînant la chute de la libération de l’IL 1β. De plus, nous avons montré que la supplémentation en DHA dans les MDSC exposées au 5 FU diminuait l’activité de la caspase-1 ainsi que la modification des interactions entre NLRP3 et la caspase-1, ASC ou β-arrestine-2. De manière inattendue, la régulation de l'activité de la caspase-1 par le DHA était indépendante de JNK, ce qui suggère que le DHA pourrait contrôler la sécrétion de l’IL 1β par le biais de l'inflammasome NLRP3 et de la voie JNK. Enfin, nous avons trouvé une corrélation négative entre la teneur en DHA dans le plasma et l'induction du niveau d'IL 1β ou de la caspase-1 dans le sang de patients traités par chimiothérapie à base de 5-FU.L’ensemble de ces données fournissent de nouvelles informations sur la régulation de la sécrétion de l’IL-1β par le DHA et son bénéfice potentiel dans la chimiothérapie à base de 5-FU. / A limitation to 5-Fluorouracil (5-FU) anti-cancer efficacy relies on the secretion of IL-1β by myeloid-derived suppressor cells (MDSC) according to a previous pre-clinical report. The release of mature IL-1β originates from 5 FU mediated NLRP3 activation with increased caspase-1 activity in MDSC and sustains tumor growth recovery in 5 FU treated mice. Docosahexaenoic acid (DHA) belongs to omega-3 fatty acid family and harbors both anti cancer and anti inflammatory properties which might could improve 5 FU chemotherapy. Here, we demonstrate that DHA inhibits 5 FU induced IL 1β secretion produced by a MDSC cell line (MSC-2). In tumor-bearing mice treated with 5 FU, we showed that a DHA enriched diet reduces circulating IL 1β concentration and tumor recurrence after 5 FU injection. 5 FU treatment led to JNK activation in MDSC and JNK inhibitor SP600125 decreased IL 1β secretion. Moreover, DHA was able to counteract 5 FU mediated JNK activation in MDSC leading to the drop of IL 1β release. In addition, we showed that DHA supplementation in 5 FU exposed MDSC decreases caspase-1 activity along with a modification of the interactions between NLRP3 and caspase-1, ASC or β arrestin-2. Unexpectedly, the regulation of caspase-1 activity by DHA was independent of JNK which suggests that DHA could control IL 1β secretion through both NLRP3 inflammasome and JNK pathway. Interestingly, we found a negative correlation between DHA content in plasma and the induction of circulating IL 1β level or caspase-1 activity in patients treated with 5 FU based chemotherapy.Together, these data provide new insights on the regulation of IL 1β secretion by DHA and its potential benefit in 5-FU based chemotherapy.

P2X7-Rezeptoren stellen Schlüsselmoleküle bei der Entstehung und Aufrechterhaltung proinflammatorischer Zustände, chronischer Schmerzen sowie der neuroglialen Kommunikation dar. Ihre Aktivität wird durch eine Vielzahl zellbiologischer Mechanismen beeinflusst. Dazu gehört die allosterische Modulation durch extrazelluläre niedermolekulare Stoffe. Die Entwicklung selektiver und potenter P2X7-Modulatoren ist darum Gegenstand intensiver Forschung. Bisher sind jedoch keine Pharmaka für die klinische Anwendung verfügbar. Die Untersuchung zugelassener pharmakologischer Substanzen in einem akademischen Screening erbrachte eine hohe Trefferrate für P2X7-Rezeptoren. In dieser Arbeit wird die P2X7-Wirkung einiger der potentesten allosterischen Modulatoren genauer charakterisiert. Das Antihistaminikum Clemastin stellt dabei einen positiven allosterischen Modulator dar, der den Rezeptor gegenüber niedrigeren ATP-Konzentrationen sensibilisiert. Ivermectin, ein häufig angewendetes Anthelminthikum, konnte als potenzierender Modulator des humanen P2X7-Rezeptors charakterisiert werden. Mit den Phenothiazinen Prochlorperazin und Trifluoperazin zeigen sich schließlich ZNS-gängige Inhibitoren der ATP-induzierten P2X7-Aktivität, die für weiterführende in vivo-Untersuchungen hilfreiche pharmakologische Werkzeuge darstellen können.